Hasil Pencarian - Anthony Tolcher

  • Menampilkan 1 - 8 hasil dari 8
Perbaiki Hasil
  1. 1
    530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectable tumors

    530 A first-in-human phase I study of M6223 (TIGIT inhibitor) as monotherapy or in combination with bintrafusp alfa in patients with metastatic or locally advanced solid unresectab... oleh Sen Zhang, Aung Naing, Meredith McKean, Anthony Tolcher, Geoffrey Watson, Anja Victor, Vadryn Pierre, Emilia Richter

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid tumors

    472 BDB001, a toll-like receptor 7 and 8 (TLR7/8) agonist, can be safely administered intravenously in combination with atezolizumab and shows clinical responses in advanced solid... oleh Alexander Chung, Omid Hamid, Manish Patel, Drew Rasco, Robert Andtbacka, Anthony Tolcher, Melissa Johnson, David Sommerhalder, Lixin Li

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advanced solid tumors

    First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advance... oleh Tianhong Li, Patricia LoRusso, Michael L. Maitland, Sai-Hong Ignatius Ou, Erkut Bahceci, Howard A. Ball, Jung Wook Park, Geoffrey Yuen, Anthony Tolcher

    Diterbitkan 2016-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    490 Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors

    490 Clinical benefit through Siglec-15 targeting with NC318 antibody in subjects with Siglec-15 positive advanced solid tumors oleh Omid Hamid, Anthony Tolcher, Martin Gutierrez, Elaine Shum, Linda Liu, Solomon Langermann, Zachary Cusumano, Han Myint, Jahangheer Shaik, Emilia Barbu, Qinjie Zhou, Aaron Morawski, Hasan Abukharma, Megan Nelson, Stephanie Zeidan

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    377 Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a phase 1 dose escalation study in patients with advanced solid tumors

    377 Characterization of peripheral biomarkers of GS-1423, a first in class bifunctional anti-CD73-TGFβ receptor II- trap molecule, in a phase 1 dose escalation study in patients wi... oleh Michael Gordon, Anthony Tolcher, James Strauss, Rick Sorensen, Marianna Zavodovskaya, Ping Cheng Yi, Audrey Goddard, Matthew Peach, Kathleen Mahoney, Xiaoyun Yang, Kai-Wen Lin, Biao Li, Anna Seto, Tianling Chen, Juliane Jürgensmeier

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

    377 AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects oleh Nicholas Wilson, Richard Carvajal, Irina Shapiro, Anthony Tolcher, Dhan Chand, Marc Van Dijk, Anna Wijatyk, Jennifer Buell, James Strauss, Claire Galand, Vignesh Venkatraman, Marilyn Marques, Min Lim, Benjamin Morin, Olga Ignatovich, Mark Findeis, Dennis Underwood, Lernik Ohanjanian, David Savitsky

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)

    Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181) oleh John Powderly, Alexander Spira, Shunsuke Kondo, Toshihiko Doi, Jason J. Luke, Drew Rasco, Bo Gao, Minna Tanner, Philippe A. Cassier, Anas Gazzah, Antoine Italiano, Diego Tosi, Daniel E. Afar, Apurvasena Parikh, Benjamin Engelhardt, Stefan Englert, Stacie L. Lambert, Sreeneeranj Kasichayanula, Sven Mensing, Rajeev Menon, Gregory Vosganian, Anthony Tolcher

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial

    Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial oleh Xiaoyu Zhang, Anthony M Joshua, Sanjeev Kaul, Scott Antonia, Robert L Ferris, Roger B Cohen, Ezio Bonvini, Jan Baughman, Victoria Atkinson, Charu Aggarwal, Nicholas Vogelzang, Osama Rahma, Mahesh Seetharam, Yanyan Lou, Anthony Tolcher, Fernanda I Arnaldez, Amy Prawira, Ralph Hauke, Vinod Ganju, Andrew Weickhardt, Dan P Zandberg, Arash Rezazadeh Kalebasty, Alex A Adjei, Ariel Birnbaum, Rosetta Cavallo, Linda Peng, Paul A Moore, Stacie M Goldberg, Nehal J Lakhani

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: